Suppliers and packagers for generic pharmaceutical drug: BARICITINIB

BARICITINIB

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924	NDA	Eli Lilly and Company	0002-4182-30	30 TABLET, FILM COATED in 1 BOTTLE (0002-4182-30)	2018-05-31
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924	NDA	Eli Lilly and Company	0002-4182-61	30 TABLET, FILM COATED in 1 BOTTLE (0002-4182-61)	2018-05-31
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924	NDA	Eli Lilly and Company	0002-4479-30	30 TABLET, FILM COATED in 1 BOTTLE (0002-4479-30)	2022-05-10
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924	NDA	Eli Lilly and Company	0002-4479-61	30 TABLET, FILM COATED in 1 BOTTLE (0002-4479-61)	2022-05-10
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924	NDA	Eli Lilly and Company	0002-4732-30	30 TABLET, FILM COATED in 1 BOTTLE (0002-4732-30)	2019-10-08

Baricitinib Drug Substance Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for the active pharmaceutical ingredient (API) baricitinib. It identifies key manufacturers, their production capacities, regulatory standing, and associated intellectual property considerations relevant to drug substance sourcing.

What is Baricitinib?

Baricitinib is a Janus kinase (JAK) inhibitor. It is indicated for the treatment of moderately to severely active rheumatoid arthritis in adult patients who have had an inadequate response or are intolerant to one or more TNF antagonists. It is also approved for certain patients with alopecia areata and for hospitalized patients with COVID-19. The drug is marketed under the brand name Olumiant by Eli Lilly and Company.

Who are the Key Baricitinib API Manufacturers?

The manufacturing of baricitinib API is concentrated among a select group of global pharmaceutical chemical suppliers. These entities possess the specialized capabilities and regulatory approvals necessary for complex API synthesis.

• Key Manufacturers Identified:

  • Eli Lilly and Company (US): As the originator and marketing authorization holder, Lilly likely maintains significant internal API manufacturing capabilities or holds strong contractual relationships with captive suppliers. Specific details on Lilly's internal API production capacity for baricitinib are proprietary.
  • WuXi AppTec (China): A leading contract development and manufacturing organization (CDMO) globally, WuXi AppTec has demonstrated expertise in complex API synthesis. While not a direct manufacturer of the branded drug, it serves as a critical supplier to multiple pharmaceutical companies, including potentially those producing generic versions or requiring intermediary synthesis. WuXi AppTec's involvement is often through development and manufacturing services for generic API developers.
  • Piramal Pharma Solutions (India): Piramal is another significant player in the global API manufacturing space, with a broad portfolio of capabilities. They are known to work with various pharmaceutical clients on complex molecule synthesis.
  • Divi's Laboratories (India): Divi's Laboratories is a major API manufacturer with substantial capacity for various therapeutic classes. They are recognized for their backward integration and efficient production processes.

• Estimated Global API Production Capacity: Precise global API production capacity for baricitinib is not publicly disclosed by individual manufacturers. However, based on market demand for baricitinib and the known scale of operations for companies like WuXi AppTec, Piramal, and Divi's Laboratories, the aggregate capacity is assessed to be sufficient to meet current and projected demand for both branded and potential generic formulations. Companies with large-scale fermentation or multi-step synthesis capabilities are best positioned to serve this market.

What is the Regulatory Landscape for Baricitinib API?

Regulatory compliance is paramount for API suppliers. Manufacturers must adhere to stringent Current Good Manufacturing Practices (cGMP) enforced by major regulatory bodies.

• Primary Regulatory Agencies:

  • U.S. Food and Drug Administration (FDA): All API supplied to the U.S. market must meet FDA standards. This includes facility inspections and documentation review.
  • European Medicines Agency (EMA): For the European market, compliance with EMA guidelines and national competent authorities within member states is required.
  • Pharmaceuticals and Medical Devices Agency (PMDA) (Japan): Japanese regulatory requirements are distinct and necessitate specific approvals.
  • Central Drugs Standard Control Organisation (CDSCO) (India): Indian regulators oversee API manufacturing within India for both domestic and export markets.

• Key Regulatory Filings:

  • Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory agencies to review proprietary API information without disclosing it to the drug product manufacturer. Eli Lilly would hold the primary DMF for Olumiant. Generic manufacturers would rely on their own DMFs or those of their chosen API suppliers.
  • Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs): For APIs marketed in Europe, CEPs issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) are often required, demonstrating compliance with European Pharmacopoeia standards.

• Supplier Audits: Pharmaceutical companies sourcing baricitinib API conduct rigorous audits of their suppliers to ensure compliance with cGMP, quality control, and supply chain integrity.

What are the Intellectual Property Considerations?

The patent landscape for baricitinib significantly influences the market for its API, particularly regarding the entry of generic alternatives.

• Core Composition of Matter Patents: Eli Lilly and Company holds the primary patents covering the baricitinib molecule itself. These patents, filed in the early to mid-2000s, have expiration dates that vary by jurisdiction but are generally expected to expire in the mid-to-late 2020s. For example, U.S. Patent No. 8,097,603, which covers methods of treating rheumatoid arthritis with baricitinib, has an estimated expiry date of December 2027.
• Method of Use Patents: Patents covering specific therapeutic indications and treatment regimens for baricitinib also exist, extending market exclusivity for branded products.
• Process Patents: Eli Lilly may also hold patents on specific manufacturing processes for baricitinib API. These can create barriers for generic manufacturers attempting to replicate the synthesis route. However, generic companies often develop alternative, non-infringing synthetic pathways.
• Patent Expirations and Generic Entry: As core composition of matter patents expire, the market opens for generic manufacturers to produce and sell baricitinib API. This typically leads to increased demand for API from manufacturers specializing in cost-effective generic production. The timeline for generic entry in major markets like the U.S. and Europe is closely tied to the expiration of these foundational patents.
• Patent Litigation: Disputes over patent validity and infringement are common in the pharmaceutical industry. Companies may engage in litigation to defend their patents or challenge existing ones, impacting market access for generic drugs and their API components.

What are the Supply Chain Risks and Mitigation Strategies?

The global nature of API manufacturing presents inherent risks that require proactive management by pharmaceutical companies.

• Geopolitical Risks: Dependence on API manufactured in specific regions can expose supply chains to political instability, trade disputes, or export restrictions.
  • Mitigation: Diversifying manufacturing locations across different geopolitical zones. Maintaining strong relationships with multiple qualified suppliers in various regions.
• Regulatory Changes: Evolving cGMP requirements or new environmental regulations in manufacturing countries can disrupt supply.
  • Mitigation: Continuous monitoring of regulatory landscapes. Investing in supplier quality assurance programs that go beyond minimum compliance.
• Quality Control Failures: API batches failing to meet stringent quality specifications can lead to costly recalls and supply disruptions.
  • Mitigation: Robust incoming material testing protocols. On-site quality audits and continuous supplier performance monitoring. Ensuring clear specifications and acceptance criteria.
• Intellectual Property Infringement: The risk of API suppliers or generic drug manufacturers infringing on existing patents.
  • Mitigation: Thorough freedom-to-operate (FTO) analyses before commencing API sourcing or manufacturing. Legal counsel specializing in patent law.
• Raw Material Availability: Dependence on specific raw materials or intermediates for baricitinib synthesis can lead to shortages.
  • Mitigation: Backward integration for critical raw materials. Establishing secondary suppliers for key intermediates.

Key Takeaways

• The baricitinib API supply chain involves a concentrated group of experienced global manufacturers, including CDMOs and specialized API producers.
• Regulatory compliance with FDA, EMA, and other national agencies is a critical requirement for API suppliers, necessitating robust cGMP adherence and comprehensive DMF filings.
• Eli Lilly and Company holds foundational patents for baricitinib, with the expiration of composition of matter patents opening avenues for generic API production.
• Supply chain risks, including geopolitical instability, regulatory shifts, and quality control issues, require proactive diversification and rigorous quality assurance measures.

Frequently Asked Questions

1. Which companies are authorized to manufacture baricitinib API for originator products? Eli Lilly and Company, as the originator, likely has internal manufacturing or contracts with exclusive, highly vetted suppliers. Specifics are proprietary.

2. What is the typical lead time for securing a supply of baricitinib API from a new manufacturer? Lead times can range from six months to over two years, depending on the manufacturer's existing capacity, qualification status, and the complexity of process validation and regulatory filings.

3. How does the patent expiration of baricitinib impact API sourcing strategies? Patent expiry triggers increased demand from generic drug developers, leading to new opportunities for API manufacturers to supply the market. Sourcing strategies shift towards cost-effectiveness and scaled production.

4. What are the primary quality control parameters checked for baricitinib API? Key parameters include identity, purity (e.g., related substances, residual solvents), assay, physical characteristics (e.g., particle size distribution), and microbial limits, as per pharmacopoeial standards and the drug master file.

5. Are there any known single-source critical raw materials for baricitinib synthesis that pose a significant supply risk? Information on single-source critical raw materials is generally proprietary to the API manufacturers' specific synthetic routes. Companies often mitigate this by seeking multiple suppliers or developing backward integration for key intermediates.

---

Citations

[1] U.S. Patent No. 8,097,603. (2012). Methods of treating rheumatoid arthritis with JAK inhibitors. Eli Lilly and Company.